

VU Research Portal

Immunodiagnostics and immune surveillance in an era of evolving immunotherapeutic strategies in AML

van den Ancker, W.

2013

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

van den Ancker, W. (2013). *Immunodiagnostics and immune surveillance in an era of evolving immunotherapeutic strategies in AML*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of Contents

	List of abbreviations	8
<i>Chapter 1</i>	General introduction	13
PART 1		
<i>Chapter 2</i>	Immunophenotyping of acute leukemia: introduction into the WHO2008 <i>NTVH 2009;6:205-10</i>	19
<i>Chapter 3</i>	The role of flow cytometry in diagnosing acute leukemias: two case reports <i>Leuk Res. 2009 Jul;33(7):e77-80</i> <i>Leuk Res. 2011 May;35(5):693-6</i>	31
<i>Chapter 4</i>	Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification <i>Leukemia. 2010 Jul;24(7):1392-6</i>	43
<i>Chapter 5</i>	A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin <i>Cytometry B Clin Cytom. 2013 Jan 16</i>	53
<i>Chapter 6</i>	MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia <i>Clinical cancer research 2013, ahead of print</i>	65
PART II		
<i>Chapter 7</i>	Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia <i>Immunotherapy. 2010 Jan;2(1):85-97</i>	91
<i>Chapter 8</i>	High class II-associated invariant chain peptide (CLIP) expression on aberrant myeloid progenitor cells is associated with increased relapse risk in acute myeloid leukemia <i>Submitted</i>	109
<i>Chapter 9</i>	Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells <i>Cancer Res. 2011 Apr 1;71(7):2507-17</i>	119



PART II

- Chapter 10* The role of immunotherapy in leukemia 139
Immunotherapy. 2010 Jan;2(1):69-83
Handb Exp Pharmacol. 2009;(188):319-48
- Chapter 11* Priming of functional PRAME and WT1 specific CD8+ T cells in healthy donors but not in AML patients in first complete remission: implications for immunotherapy 161
Oncoimmunology. 2013 Apr 1;2(4):e23971.
- Chapter 12* Procedures for the expansion of CD14+ precursors from acute myeloid leukemic cells to facilitate dendritic cell based immunotherapy 173
Immunotherapy, ahead of print
- Chapter 13* CML lysate-loaded dendritic cells induce specific T cell responses towards leukemia progenitor cells indicating their potency for application in active specific immunotherapy 189
Immunotherapy. 2011 Apr;3(4):569-76
- Chapter 14* Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation 203
Cancer Immunol Immunother. 2011 Jan;60(1):37-4
- Chapter 15* Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines 219
Submitted

PART IV

- Chapter 16* Genereal discussion and future perspectives 237
Nederlandse samenvatting voor niet ingewijden 247

